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ethyl alcohol ͉ fetal alcohol spectrum disorders ͉ photolabel F etal alcohol syndrome (FAS) is the most common preventable cause of mental retardation in the Western world, occurring in 1-5 per 1,000 live births (1) . Severe cases are characterized by growth deficiency, neurological abnormalities, and facial malformations (2) . Prenatal ethanol exposure also results in diverse birth defects and neurobehavioral abnormalities in up to 1 per 100 live births (1) ; the spectrum of these abnormalities is referred to as fetal alcohol spectrum disorders (FASD) (2) .
Several lines of evidence support the hypothesis that ethanol causes FASD in part by disrupting the function of the L1 cell adhesion molecule (3, 4) . First, L1 gene mutations are associated with some of the same structural brain abnormalities observed in FASD: hydrocephalus, agenesis or hypoplasia of the corpus callosum, and cerebellar dysplasia (4) (5) (6) . Second, ethanol disrupts the function of L1 at concentrations that are attained after one or two drinks. Ethanol inhibits L1-mediated cell-cell adhesion (L1 adhesion) in NG108-15 neuroblastoma ϫ glioma hybrid cells, cerebellar granule cells, and selected human L1-transfected murine fibroblasts (3, 4, 7) . Low concentrations of ethanol also inhibit L1-mediated neurite outgrowth (8) . Third, drugs that block ethanol inhibition of L1 adhesion also prevent ethanol teratogenesis in mouse embryos (9-12).
The pharmacology of alcohol inhibition of L1 adhesion is consistent with a ligand-receptor interaction. The concentrations of ethanol that affect L1 function are among the lowest reported for any ethanol target (4, 8) , and the ability of other alcohols to inhibit L1 adhesion is subject to surprisingly strict structural requirements (13, 14) . Within the 1-alcohol series, methanol through 1-butanol show progressively increasing potency, whereas 1-pentanol and higher 1-alcohols are inactive, consistent with a size limitation for alcohol interactions with a hydrophobic site on L1 (4) . Also, the agonist activity of 1-butanol, the most potent alcohol agonist, is eliminated by chemical modifications that constrain movement between carbon 3 and 4 or sterically hinder its hydroxyl group (13, 14) . Finally, 1-octanol and a number of alcohols and small peptides that lack agonist activity block ethanol inhibition of L1 adhesion (10, 11, (13) (14) (15) . In mouse embryos several of these ethanol antagonists also prevent ethanol-induced apoptosis, growth retardation, and delayed closure of the neural tube (9-12, 16, 17) . These data support the hypothesis that ethanol acts at a binding site on L1 to disrupt its function. Because the extracellular domains of L1 are critical for L1 adhesion (18) , these domains are candidate locations for putative alcohol binding sites.
L1 comprises six I-set Ig domains, five fibronectin III (FNIII) repeats, a short transmembrane domain, and an intracellular domain (Fig. 1) . A long linker region between Ig2 and Ig3 enables the Ig1 and Ig2 domains to fold over and contact the Ig3 and Ig4 domains, forming a horseshoe structure that may facilitate L1-L1 interactions (18) (19) (20) . The importance of this quaternary structure on L1 function is suggested by the disproportionate number of disease-causing missense mutations located at Ig domain interfaces, many of which reduce L1 homophilic binding (21, 22) .
Alcohol binding sites on proteins cannot be demonstrated by classic radioligand binding assays because of the low affinity of alcohols for their targets. Recently, a new strategy has been developed for locating alcohol binding sites. Azialcohols, bearing a photolabile diazirine moiety on one carbon, are stable general anesthetics with normal potencies that obey the MeyerOverton rule. Since their introduction (23) , azialcohols have been used to locate binding sites on the nicotinic acetylcholine receptor (24) , protein kinase C (25) , and adenylate kinase (26) .
Here we establish that 3-azibutanol inhibits L1 adhesion (agonist action), whereas 3-azioctanol potently blocks ethanol inhibition of L1 adhesion (antagonist action). Significantly, photolabeling revealed a common binding site for 3-azibutanol and 3-azioctanol at the domain interface between Ig1 and Ig4 in close proximity to disease-causing mutations.
Results
Azialkanol Action on Cell Adhesion. 3-Azibutanol (14 mM) reduced L1 adhesion in 2A2-L1 NIH/3T3 fibroblasts (Fig. 2) to the same extent as ethanol (100 mM) and 1-butanol (6 mM), indicating that the addition of the diazirine group did not reduce the agonist action of 1-butanol. When added alone to the cells, 14 M 3-azioctanol had no effect on cell viability (data not shown), nor did it significantly change L1 adhesion. However, 14 M 3-azioctanol completely antagonized ethanol inhibition of L1 adhesion. The effects of 3-azibutanol and 3-azioctanol are comparable to those reported for other alcohol antagonists and antagonists (14) . These data establish that 3-azibutanol and 3-azioctanol are suitable photolabels to probe alcohol binding sites that modulate L1 adhesion.
Photolabeling with the Agonist 3-Azibutanol. We next used these agents to locate binding sites on hL1 Ig1-4, an appropriately sized protein for tandem MS (MS/MS) identification of photolabeled peptides and the smallest fragment of L1 that exhibits homophilic binding (22, 27) . To minimize nonspecific binding, we photolabeled at decreasing concentrations until little photoincorporation could be detected. This titration strategy was adopted because the exchange rate of alcohols is too high to allow a reversible ligand to compete with an irreversible one on the time scale of a photolabeling experiment. At 50 M 3-azibutanol no photolabeled tryptic peptides were detected, whereas at 100 M and 1 mM 3-azibutanol one and four such peptides, respectively, could be reproducibly sequenced.
The single photolabeled tryptic peptide from the 100 M 3-azibutanol photolabeling had a mass of 2,056.3728, a charge of 2, and an HPLC retention time of 6.7 min. It was identified as an 18-residue peptide, starting at His-410, HGLLLANAYIYV-VQLPAK. Fig. 3 shows that a run of strong modified y-ions from y17 to y10 was interrupted at y9 (not observed). A second run of strong y-ions from y8 to y3 were all unmodified. This suggests that either Tyr-418 or Ile-419 is photolabeled. This ambiguity is resolved by a run of mostly strong b-ions from b15 to b10, all of which are modified, a strong unmodified b8 ion, and a second run of unmodified b-ions from b6 to b3. Thus, photoincorporation is located at Tyr-418. This assignment was confirmed in chymotrypsin digests, which yielded a peptide starting at Leu-410 that was consistently photolabeled with 100 M 3-azibutanol at Tyr-418 (data not shown).
Trypsin digestion enabled the sequencing of 87% of the residues within hL1 Ig1-4, and chymotrypsin digestion extended this coverage to a total of 95% [see supporting information (SI) Table 1 ]. Only one additional photolabeled peptide was identified in the chymotrypsin digest of samples photolabeled with 100 Fig. 1 . The domain structure of the neural cell adhesion molecule L1, showing the six Ig, five FNIII, transmembrane, and cytoplasmic domains. Numbers indicate amino acid residues. In the CAM superfamily, L1 is distinguished by its long N terminus and extra residues in the Ig2-3 loop enabling the folded, horseshoe structure shown. Ig1-4 domains are color-coded consistently throughout the figures. Fig. 2 . Azialcohols act on cell adhesion like their parent alcohols. Cell adhesion assays were performed on 2A2-L1 cells in the absence (Control, black bar) and presence of the indicated alcohols. Bars represent the mean percentage (Ϯ SEM) for L1 adhesion based on three to five replicates. The agonist alcohols (light gray bars) all inhibited L1 adhesion compared with control. * , P Յ 0.05; ** , P Ͻ 0.01 (one-way ANOVA with Dunnett's test for multiple comparisons) at concentrations of 100 mM ethanol, 6 mM 1-butanol, and 11 mM 3-azibutanol. The antagonist 3-azioctanol had no effect on L1 adhesion at 14 M. The antagonists 1-octanol (50 M) and 3-azioctanol (14 M) (dark gray bars) completely reversed the action of the agonist ethanol (100 mM). (Inset) On the left is 3-azibutanol, and on the right is 3-azioctanol. M 3-azibutanol. This was a 26-residue peptide from the Nterminal domain starting at Ile-20, IQIPEEYEGHHVMEP-PVITEQSPRRL, which eluted at 14 min and had a mass of 3,158.4709, a charge of 5, and an ion current somewhat greater than the photolabeled tryptic fragment. Unlike the peptide containing Tyr-418, this peptide photoincorporated 3-azibutanol at more than one site, as evidenced by peptides observed with lower frequency that had a mass of 3,230.47093 or 3,302.47093, corresponding to double and triple photoincorporation, respectively. Although a consistent pattern of labeling emerged, sequencing by MS/MS was more challenging. A peptide with Glu-33 photolabeled eluted earlier than one with either Glu-24 or Glu-25 photolabeled. In the latter peptide photoincorporation at Glu-24 or Glu-25 fitted the data best and strongly discriminated against Glu-33. In the former peptide, although Glu-33 best fit the data, Glu-24 and Tyr-26 were not strongly discriminated against. At 1 mM 3-azibutanol some scans reliably showed photolabeling at Glu-33 and not at Glu-24 to Glu-27, and others vice versa (see, for example, SI Fig. 5 and SI Table 2 ). Thus, we conclude that there are two loci of photoincorporation on this peptide, one at Glu-33 and the other between Glu-24 and Glu-27. Taken together, our data demonstrate that 3-azibutanol photolabels Tyr-418 and Glu-33 along with one or more residues between Glu-24 and Glu-27.
Photolabeling with the Antagonist 3-Azioctanol. At a high concentration of 1 mM 3-azioctanol, 12 photolabeled tryptic peptides were identified by mass, and six of them were reliably sequenced. In contrast, at 10 M 3-azioctanol, only one photolabeled tryptic peptide was detected. This peptide had a mass of 2,112.3728, a charge of 3, and an HPLC retention time of 22.0 min and was reliably sequenced (see SI Fig. 6 ) by MS/MS. Its sequence was HGLLLANAYIYVVQLPAK, starting at His-410, and photoincorporation of 3-azioctanol was located at Tyr-418, the same residue photolabeled by 3-azibutanol. This identification was also achieved at 100 M 3-azioctanol (SI Fig. 7) .
A chymotrypsin digest of hL1 Ig1-4 photolabeled with 100 M 3-azioctanol yielded a single modified peptide that had a mass of 3,214.47093 and a charge of 3. It was identified as the 26-residue peptide starting at Ile-20, IQIPEEYEGHHVMEP-PVITEQSPRRL, the same peptide photolabeled by 3-azibutanol. Of the eight scans sequenced by MS/MS, two unequivocally identified Glu-33 as the residue photolabeled, and two unequivocally identified Glu-24. Three other scans failed to discriminate among Tyr-26, Glu-27, and Glu-24. After photolabeling with 10 M 3-azioctanol, doubly photolabeled peptides were observed whose intensity was too low to be reliably sequenced. However, at higher concentrations of 3-azioctanol (1 mM), doubly labeled peptides could be sequenced. In one, the neighboring residues Glu-24 and Glu-25 were unequivocally labeled. In the other, Glu-33 and Tyr-26 were labeled (SI Fig. 8 ).
We were able to independently confirm the photolabeling by 3-azioctanol of Glu-33 by making use of the fact that mouse L1 has an extra tryptic cleavage site introduced by a hGlu-27 to mLys-27 substitution. Accordingly, we photolabeled a sample of mouse L1 Ig1-6-Fc, kindly provided by Martin Grumet (Rutgers University, Piscataway, NJ), with 1 mM 3-azioctanol. Tryptic digest revealed a triply charged, modified peptide with mass 1,925.01 eluting at 21 min, somewhat after the broad parent peak. The 16-residue tryptic peptide was identified as GHHV-LEPPVITEQSPR, starting at Gly-28. MS/MS analysis revealed the site of photoincorporation to be Glu-33 (SI Fig. 9) .
Thus, the data for both 3-azibutanol and 3-azioctanol are consistent with one site of photoincorporation at Tyr-418 and two sites of photoincorporation in the N-terminal region, one at the Glu-24-Glu-27 locus and the other at Glu-33.
Homology Model of hL1 Ig1-4. To better appreciate the location of these sites, we constructed a homology model of residues 33-424 of hL1 Ig1-4 based on axonin Ig1-4, the largest fragment of any L1 superfamily member to be crystallized to date (27) . In the Ramachandran plot of the model shown in Fig. 4 , Ͼ79.5% of the residues (excluding Gly and Pro) had -angles in the most favored region, 18.1% in the allowed regions, and 0.6% in the generously allowed region. Of the 1.8% of the residues in the disallowed region, many were in either loop regions or regions of low homology. Compared with the experimentally determined structure of axonin, the rmsd of the 104 identical residues, calculated by using top3d, was 0.97 Å, which lies in the acceptable range for models with this level of structural homology (28) .
The model's most notable feature is an almost globular or horseshoe-shaped structure, in which Ig1 lies opposed to Ig4 and Ig2 lies opposed to Ig3 in antiparallel fashion (Fig. 4) . This folded structure is enabled by a linear stretch of amino acids between Ig2 and Ig3, shown in purple, that is unique to the L1 family of cell adhesion molecules (18) . The model predicts that two photolabeled residues, Glu-33 and Tyr-418, although widely separated on the primary sequence, are situated in close prox- imity at the domain interface between Ig1 and Ig4. Indeed, the 1 oxygen of Glu-33 lies just 2.8 Å from the oxygen (hydroxyl) of Tyr-418, forming a strong hydrogen bond. This alcohol binding pocket also abuts two residues, Leu-120 and Gly-121, at which missense mutations cause disease (6) .
Discussion
This study tested the hypothesis that there are binding sites for alcohol agonists and antagonists on the extracellular domain of L1. To identify an agonist binding site we used 3-azibutanol, a photolabel that mimicked the actions of ethanol and 1-butanol to inhibit L1 adhesion. To identify an antagonist binding site we used 3-azioctanol, a photolabel that blocked the effects of ethanol on L1 adhesion. For both the agonist and antagonist photolabel, titration from higher to lower concentrations eliminated the photolabeling of all but three sites. Strikingly, at the lowest concentrations tested, both the agonist and the antagonist photolabeled the same sites: Tyr-418 on the Ig4 domain and Glu-33 at the start of Ig1. Both 3-azibutanol and 3-azioctanol photolabeled an additional region between Glu-24 and Glu-27, although the identification of specific photolabeled residues was less reliably determined.
We constructed a homology model of Ig1-Ig4 of L1 to determine the location of the photolabeled residues in relation to the three-dimensional structure of L1. Our model, based on the crystal structure of axonin (27) , predicted a horseshoe structure similar to previous models based on the crystal structures of telokin and hemolin (19, 29) . The predicted distance of 2.8 Å between the photolabeled residues Glu-33 and Tyr-418 suggests that these two residues form a strong hydrogen bond that stabilizes the domain interaction between Ig1 and Ig4 and the horseshoe structure. A limitation of our model is the absence of a homologous structure containing any of the first 32 aa of L1. Therefore, we are unable to predict the location of the photolabeled residues within the Glu-24-to-Glu-27 segment in relation to this alcohol binding pocket. The issue of whether these residues form part of the same pocket or a second site can be resolved only with more structural information.
Electron microscopic studies reveal both a linear and a horseshoe conformation for the first six Ig domains of human L1 (20) . Haspel and Grumet (18) have proposed that the Ig1-Ig4 domains of L1 interconvert between the horseshoe and linear conformation, with homophilic binding favored by the horseshoe conformation. Indeed, binding of neurocan to L1 may inhibit L1 homophilic adhesion by stabilizing the linear conformation of Ig1-4 (18) . The potential importance of the horseshoe structure of L1 is underscored by the conservation of residues across species at the domain interfaces between Ig1 to Ig4 and Ig2 to Ig3 and the disproportionate number of these residues in which missense mutations cause developmental abnormalities of the nervous system (21, 22, 29) .
Binding of ethanol to the Glu-33-Tyr-418 pocket could perturb L1 function in several ways. First, ethanol could inhibit homophilic binding by disrupting one of the four hydrogen bonds between Ig1 and Ig4 that stabilize the horseshoe conformation of L1. Second, the Glu-33-Tyr-418 binding pocket lies in close proximity to two disease-causing residues: Leu-120 and Gly-121. The side chain ␦-methyl group of Leu-120 is only 4.7 Å from the ␣-carbon of Glu-33 and 6.7 Å from the aromatic ring of Tyr-418, distances that are comparable to the lengths of extended ethanol (3.75 Å) and octanol (10 Å) molecules. The Leu-120-Val mutation results in the loss of Sema3A regulation of L1-neuropilin interactions but does not affect L1 homophilic binding (30) . On the other hand, the Gly-121-Ser mutation reduces L1 homophilic binding by 90% and decreases L1 interactions with F11 and contactin (21) . Thus, the binding of ethanol in the region of these disease-causing mutations could disrupt development by inhibiting homophilic or heterophilic interactions of L1.
The heavily photolabeled fragment from Glu-24 to Glu-33 includes the residues encoded by exon 2 (26-Tyr-Glu-Gly-HisHis-Val). Exon 2 is selectively expressed in the nervous system, is critical for L1 homophilic binding, and supports L1-mediated neurite outgrowth (31, 32) . Moreover, mutations in the exon 2 gene result in severe neurological disease (33) . Therefore, the binding of ethanol in the region encoded by exon 2 could also disrupt L1 function.
If azioctanol, an alcohol antagonist, photolabels the same residues as azibutanol, an alcohol agonist, then why does 1-octanol not inhibit L1 adhesion? We propose that when small alcohols, such as ethanol or butanol, bind to this locus, they weaken the hydrogen bond between Glu-33 and Tyr-418 and so alter the interaction between Ig1 and Ig4. The binding of longer alcohols in the same location as ethanol would also be expected to weaken bridging hydrogen bonds between Ig1 and Ig4. However, in contrast to ethanol, the additional methylene groups of the 1-octanol molecule fill more of the gap between the Ig1 and Ig4 domains; the consequent increase in van der Waals forces would help stabilize the Ig1-Ig4 interaction, offsetting the disruption of the hydrogen bond between Glu-33 and Tyr-418. This stabilization of the Ig1-Ig4 interaction could also account for the ability of 1-octanol to antagonize ethanol inhibition of L1 adhesion. Alternatively, long 1-alcohols might sterically hinder the interactions of ethanol with the Glu-33-Tyr-418 hydrogen bond.
Our data support the hypothesis that ethanol binds directly to the extracellular domain of L1 to perturb its function and cause teratogenesis. The alcohol binding pocket is located at a critical domain interface in close proximity to sites where gene mutation causes severe neurological disease. Site-specific mutagenesis and x-ray crystallography of L1 will be required to demonstrate the contribution of individual residues to the binding of ethanol and ethanol antagonists within this alcohol binding pocket. The detailed characterization of the three-dimensional structure of the alcohol binding pocket in L1 will assist in the rational design of molecules that might prevent FASD.
Materials and Methods
Materials. 3-Azioctanol and 3-azibutanol were synthesized as described previously (23, 26) .
Cell Culture. Cells were cultured by using standard methods. Two subclones were used: 2A2-L1 and Vec-1A5. The 2A2-L1 cell line is an ethanol-sensitive cell line derived from a stable transfection of NIH/3T3 cells with full-length human L1 cDNA; Vec-1A5 is a subclone from a transfection with the empty expression vector (7) .
The Ig1-4 portion (residues 1-422) of the human L1 gene (34) fused with a cleavable Fc fragment (TEV-Fc) at the C terminus (hL1 Ig1-4-TEV-Fc) was expressed in HEK293 cells. The secreted hL1 Ig1-4-TEV-Fc was purified by protein-A agarose affinity chromatography, digested with AcTEV protease (Invitrogen), and purified with protein-A and Ni-NTA resin to remove the Fc fragment and the TEV protease, respectively. The purity of hL1 Ig1-4 was verified by SDS/PAGE with silver staining of a single band with molecular mass of Ϸ60 kDa.
Cell Adhesion Assay. Cell-cell adhesion was measured by using a modified short-term aggregation assay of subconfluent cells as reported previously (7) . Cells were detached by gentle agitation with calcium-and magnesium-free PBS supplemented with 2 mM EDTA and 0.1 mg/ml DNase, mechanically dissociated to obtain a single-cell suspension, and diluted to 330,000 cells per milliliter. One milliliter of the cell suspension was added per 4.5-cm 2 well to a 12-well plate. Cells were viewed at a final magnification of ϫ200, and each well was scored for single and adherent cells in five or six microscopic fields of view. We counted Ϸ150 -200 cells per field of view and 750 -1,200 cells per well. The percentage of adherent cells was calculated for each microscopic field of view and averaged. L1-mediated cell adhesion was defined as the difference in the percentage of adherent cells between the L1-transfected cell line (2A2-L1) and the vector-transfected cell line (Vec-1A5). This component of cell adhesion is fully inhibited by Fab fragments of an anti-L1 polyclonal antibody (7) . Ethanol inhibition of cell adhesion was calculated as 100 ϫ (1 Ϫ the ratio of L1-mediated cell-cell adhesion in the presence and absence of ethanol).
Photolabeling Experiments. Azialcohols in water (60 l) were added to hL1 Ig1-4 (35 g in 180 l of buffer), incubated for 20 min, and irradiated at 365 nm for 45 min in a glass 96-well plate on ice. In-gel digestions were carried out following Shevchenko and Shevchenko (35) using modified sequencing-grade trypsin at 4°C (Promega) or chymotrypsin at 25°C (Roche).
Mass Spectrometry. Digested samples were reconstituted in 5 l of polar solvent (2.5% acetonitrile/0.1% formic acid) and subjected to nanoscale reverse-phase (C18) HPLC using a linear gradient of increasing concentrations of the organic solvent (acetonitrile with 0.1% formic acid) from 10 -38% over 30 min, followed by a set increase to 100%. Eluted peptides were analyzed by electrospray ionization in an LTQ-FT mass spectrometer (ThermoFinnigan). Tandem mass spectra were analyzed by using the program SEQUEST (ThermoFinnigan), which compares the calculated m/z for all possible b-and y-ions, including modifications, to the experimental spectrum.
Homology Model of hL1 Ig1-4. The sequence identity between hL1 Ig1-4, residues Glu-33 to Gln-422, and axonin-1 is 29.3%. This axonin structure includes just the Ig1-4 domains because this is the largest fragment of a homologous protein to have been crystallized. The homology model of the hL1 was built by using the EsyPred3D server (www.fundp.ac.be/sciences/ biologie/urbm/bioinfo/esypred) (36) . The model was subjected to molecular dynamics, and the energy was minimized to the stable conformation. The geometry of the final model was assessed by PROCHECK (37) .
